SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION

Supplemental Balance Sheet Information

Inventory consisted of the following:


	September 30, 2022		December 31, 2021
Raw materials	$	109,480	$	80,269
Work-in-process	425,505		415,261
Finished goods	304,475		281,139
Total inventory	$	839,460	$	776,669

Property, Plant and Equipment, Net consisted of the following:


	September 30, 2022		December 31, 2021
Property, plant and equipment, gross	$	1,834,220	$	1,756,035
Accumulated depreciation	(782,399)		(720,574)
Total property, plant and equipment, net	$	1,051,821	$	1,035,461

Depreciation expense, net of amounts capitalized into inventory, for the three and nine months ended September 30, 2022 was $8.7 million and $29.9 million, respectively. Depreciation expense, net of amounts capitalized into inventory, for the three and nine months ended September 30, 2021 was $11.4 million and $35.7 million, respectively.

Intangible Assets, Net consisted of the following:


	September 30, 2022		December 31, 2021
Finite-lived intangible assets	$	690,334	$	677,350
Accumulated amortization	(336,310)		(288,698)
Net carrying value	$	354,024	$	388,652

Accounts Payable and Accrued Liabilities consisted of the following:


	September 30, 2022		December 31, 2021
Accounts payable and accrued operating expenses	$	207,165	$	199,678
Accrued compensation expense	161,112		204,446
Accrued rebates payable	71,653		47,987
Accrued royalties payable	14,487		15,215
Foreign currency exchange forward contracts	13,075		6,263
Lease liabilities	9,226		10,464

Accrued income taxes	7,573		1,213
Deferred revenue	415		6,956
Other	8,011		6,043
Total accounts payable and accrued liabilities	$	492,717	$	498,265

Supplemental Statement of Comprehensive Income (Loss) Information

Gain on Sale of Nonfinancial Assets, Net for the nine months ended September 30, 2022 consisted of the completed sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the Food and Drug Administration (FDA) in connection with the U.S. approval of VOXZOGO. As a result of the PRV sale, the Company recognized a $108.0 million net gain on sale of nonfinancial assets in the first quarter of 2022 in the Company's Consolidated Statement of Comprehensive Income.